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Background: This work aims to add evidence and provide an update on the classification and diagnosis of
monoclonal immunoglobulin deposition disease (MIDD) and primary central nervous system low-grade lymphomas.
MIDD is characterized by the deposition of light and heavy chain proteins. Depending on the spatial arrangement
of the secreted proteins, light chain-derived amyloidosis (AL) can be distinguished from non-amyloid light chain
deposition disease (LCDD). We present a case of an extremely rare tumoral presentation of LCDD (aggregoma) and
review the 3 previously published LCDD cases and discuss their presentation with respect to AL.
Case presentation: A 61-year-old woman presented with a 3½-year history of neurologic symptoms due to a
progressive white matter lesion of the left subcortical parieto-insular lobe and basal ganglia. 2 former stereotactic
biopsies conducted at different hospitals revealed no evidence of malignancy or inflammation; thus, no therapy
had been initiated. After performing physiological and functional magnetic resonance imaging (MRI), the tumor
was removed under intraoperative monitoring at our department. Histological analysis revealed large amorphous
deposits and small islands of lymphoid cells.
Conclusion: LCCD is a very rare and obscure manifestation of primary central nervous system low-grade lymphomas
that can be easily misdiagnosed by stereotactic biopsy sampling. If stereotactic biopsy does not reveal a definite result,
a “wait-and-see” strategy can delay possible therapy for this disease. The impact of surgical removal, radiotherapy and
chemotherapy in LCDD obviously remains controversial because of the low number of relevant cases.
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Primary central nervous system lymphomas (PCNSL)
are defined as non-Hodgkin’s (NHL) lymphomas that
primarily arise in the central nervous system [1]. PCNSL
account for approximately 1–2% of all primary cerebral
tumors, and approximately 98–99% are classified as diffuse
B-cell lymphoma (analogous to systemic B-cell NHL) [2,3].
Intracerebral manifestations of T-cell lymphomas and sec-
ondary lymphomas are extremely rare [3]. Low-grade
PCNSL represents a less aggressive subgroup compared
with systemic NHL and accounts for approximately 3–20%
of all PCNSL [4,5]. Only a few low-grade PCNSL are
associated with the deposition of monoclonal light and
heavy chain immunoglobulins (Ig).
Monoclonal immunoglobulin deposition disease (MIDD)
is characterized by the deposition of monotypic light and/or
heavy chain proteins in various tissues and organs. MIDD
mainly affects the kidneys, but the involvement of other
organs (e.g., the liver, heart and peripheral nerves) is not
uncommon [6]. All forms of MIDD can be ascribed to
monoclonal expansion of an immunoglobulin (Ig) light
and/or heavy chain producing B-cells [7]. 2 subgroups
of MIDD can be differentiated histologically based on
the different spatial arrangement of the secreted proteins.
In the more common subgroup, the light chain-derived
amyloidosis (AL) subgroup, proteins are aggregated in
fibrils to ß-pleated sheets that stain for Congo red and
display green birefringence under polarized light [8]. The
second subgroup is characterized by ultrastructural non-
organized proteins, which aggregate in more amorphous
Congo red-negative depositions. Randall and colleagues
initially described 2 patients with the systemic deposition
of non-amyloid Ig light chains and proposed the term
light chain deposition disease (LCDD) [9]. Subsequent
reports confirmed the existence of systemic heavy chain
deposition disease (HCDD) as well as both light and heavy
chain deposition disease (LHCDD) [10].
We provide an update regarding the diagnosis and
classification of primary cerebral low-grade B-cell
lymphomas and cerebral light chain deposit diseases.
We present the case of a patient with a 3½-year progressive
hemiparesis and hemi-hypoesthesia of the right side due to
a delayed diagnosis and therapy of the extremely rare,
tumor-presenting cerebral restricted LCDD, which can be
called “aggregoma” [11]. We further present a systematic




A 61-year-old woman was admitted to our department
with progressive brachiofacially accentuated hemiparesis,
dysdiadochokinesia and hemi-hypoesthesia of the right side
of the body, which began 3½ years previous. She initiallypresented with dyspraxia and fluctuating hypoesthesia of
the right hand at the end of 2006; her cranial nerves were
not affected. She complained of increased fatigue but
did not present with weight loss, night sweats, fever or
headache. The woman had a history of hypothyroidism
related to Hashimoto’s thyroiditis and suffered endocarditis
and streptococcal sepsis in 1982. She was under a long-
term medication treatment of 100 μg of thyroxin daily. An
MRI scan performed in May 2007 revealed a 2.8 × 2.0 ×
2.4 cm lesion of the white matter at the level of the
left subcortical parieto-insular lobe and basal ganglia
(Figure 1a). The lesion presented as hypointense on
T1-weighted scans with some regions displaying slight
enhancement after gadolinium administration and moder-
ate inhomogeneous hyperintensity on T2-weighted scans.
Blood serum inflammatory markers (leukocytes and CRP),
cerebrospinal fluid protein, and the cell count revealed no
abnormalities. A stereotactic serial biopsy was performed
in June 2007. The histological analysis demonstrated
colloidal-bodied particles with scattered single cells with
no proof of tumors or inflammatory cells. Based on
the obvious diagnosis of an atypical colloidal cyst, no
further therapy was initiated. The first control MRI
(3 months after biopsy) demonstrated no progression of the
disease. However, a clinical deterioration and progression of
the lesion (3.6 × 2.3 × 2.6 cm) (Figure 1b & 1c) at the
follow-up MRI session in July 2008 warranted a stereotactic
serial biopsy, which was conducted at a neurosurgical clinic
that specialized in stereotactic procedures. Prior to the
stereotactic surgery, CSI (chemical shift imaging) was
performed, which revealed a prominently reduced NAA
peak, an elevation of lactate and only slight alterations of
choline and creatine peaks (Figure 1d & 1e).
The histological analysis of the biopsy that was performed
in June 2007 showed a glial cyst but exhibited no evidence
of malignancy or inflammation. In May 2010, the patient
presented for the first time at our department because of
clinical and radiological progression of the disease. Surgical
resection of the lesion with a subsequent histological
diagnosis was recommended At the day of admission, the
patient displayed poorer health and a worsened nutritional
status. The neurological examination demonstrated mod-
erate hemiparesis of the right side and hemi-hypoesthesia,
including the trigeminal nerve, with no other cranial nerve
deficits. The woman had a high-grade disturbance of the
fine motor skills of the right hand, dysdiadochokinesia
of the right side and displayed an instable standing
posture and gait. Her reflexes exhibited increased
positive Troemner’s and Babinski’s signs. On the day
of admission, a control MRI that included diffusion
tensor imaging and a functional MRI were performed.
The lesion progressed in volume to 4.2 × 3.2 × 5.3 cm
(Figure 2a) with the same signal characteristics in T1- and
T2-weighted imaging; displacement of the left pyramidal
Figure 1 MRI and MR spectroscopy of the tumor. (a) Axial T2-weighted image shows a sharply demarcated, hyperintense lesion on the
posterior aspect of the left basal ganglia and the subcortical left parieto-insular lobe. The lesion affects the internal and external capsules without
reaching the insular cortex. (b) Follow-up MR imaging after 1 year demonstrates progression of the lesion size, particularly on the posterior part,
with medially located hyperintense foci corresponding to microcysts on T2-weighted imaging. (c) Coronal T1-weighted MR imaging after
gadolinium administration shows punctual enhancement within the lesion. (d) Proton MR spectroscopy using a short echo time (TE: 30 ms) on
the lateral part of the lesion reveals a reduced NAA peak and reduced lactate levels (1.3 ppm). The lactate concentration appears more prominent
on the medial part of the lesion (and correlates with the microcystic, necrotic changes observed in Figure 1b), as shown on the metabolic map
overlaid on the axial T2-weighted image (e).
Skardelly et al. BMC Neurology 2013, 13:107 Page 3 of 9
http://www.biomedcentral.com/1471-2377/13/107
Figure 2 Preoperative MRI and fiber tracking. (a) Coronal T1-weighted image after gadolinium administration shows lesion progression.
(b) The fiber tracking imaging based on the preoperatively performed diffusion tensor imaging demonstrates displacement of the corticospinal
and corticopontine tracts on the left side, whereas the body of the corpus callosum seems unaffected.
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significantly altered values of the fractional anisotropy
compared with the healthy contralateral side.
Intervention and postoperative course
The patient underwent a left-sided standard pterional
craniotomy and a removal of the lesion via a transsylvian,
transinsular approach (with respect to the displacement of
the left pyramidal and corticopontine tracts) under
continuous intraoperative monitoring with sensory
evoked and motor evoked potentials (SEPs and MEPs,
respectively). The lesion appeared intraoperatively as
an amorphous, gelatinous mass with some regions
appearing dull and lucid (Figure 3). The tumor mass could
be almost completely removed with the preservation of
the MEPs and SEPs. After the operation, the patient
exhibited increased hemiparesis of the right side with
hemiplegia of the right arm and partial facial palsy inFigure 3 Intraoperative microscopic image. The image reveals
the amorphous, gelatinous mass of the tumor.addition to a new expressive aphasia. A postoperative head
CT revealed no signs of bleeding or infarction. By the time
of discharge, the patient had partially recovered from
aphasia and was mobilized with a Zimmer frame. In the
follow-up control in the outpatients’ department after
rehabilitation in October 2010, the patient demonstrated
almost complete recovery from expressive aphasia and
had slight palsy of the marginal mandibular branch of the
facial nerve but continued to display moderate brachially
accentuated hemiparesis of the right side. Subsequently,
the department of hematooncology initiated diagnostic
staging, and no further manifestations of B-cell lymphoma
could be identified. Whole-body CT, abdominal ultrasound
and bone marrow puncture revealed no suspicious findings.
Electrophoresis showed a regular distribution and quantity
of serum proteins (7.6 g/dl) and immunoglobulins.
Additionally, there was no hint of monoclonality of
serum proteins in the immunofixation assay. Physiological
albuminuria in urine electrophoresis was observed.
Neuropathology
Histological examination of the resected tumor revealed
large, amorphous, proteinaceous eosinophilic deposits and
small islands of lymphoid cells between them (Figure 4a).
The amorphous deposits were strongly PAS positive but
negative for Congo red staining and did not display apple-
green birefringence under polarization (Figure 4b). Most
of the small lymphoid cells expressed the B-cell marker
CD20 (Figure 4c). There were also few CD3-positive
T-cell lymphocytes (Figure 4d). Immunoreactivities for
the Ig-A heavy chain (Figure 4e) and λ-light chain
immunoglobulins (Figure 4f ) were partially observed
in the deposits, plasmacytoid lymphocytes and mature
plasma cells. The plasmacytic cells expressed CD38
and CD138, whereas they were negative for C79a. There
was a negative reaction for IgM, IgG and IgE heavy chains
Figure 4 Histological analysis of the tumor. (a) Amorphous eosinophilic deposits (hematoxylin and eosin staining). (b) Amorphous deposits
are strongly PAS positive. (c) Most of the lymphoid cells express CD20. d) Few infiltrating CD3 positive T-cells are observed. Amorphous deposits
and plasmacytic cells stain positive for Ig-A heavy chain (e) and for λ-light chain antibody (f).
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proliferation rate (IHC for Ki67, 3 %). Some expressed
bcl2, a few lymphocytes expressed CD5, and there was
negative immunoreactivity for CD10, CD19, MUM1 and
bcl6. Semi-nested PCR revealed monoclonal amplification
of the complementarity-determining region III (CDR III)
of the immunoglobulin heavy chain gene [1], supporting
the diagnosis of low-grade lymphoplasmacytic lymphoma
with light chain deposition disease and IgA- and λ-light
chain restriction.
Discussion
Insoluble amyloid- or light chain-related non-amyloid
aggregates can be formed by systemically secreted
proteins, mainly involving the kidneys or occurring in
an organ-specific manner [12]. Different CNS diseasesare associated with amyloid depositions in the brain
(e.g., Alzheimer’s disease, cerebral amyloid angiopathy,
prion-related diseases or light chain-derived amyloidosis
(AL)) [13]. The organ-specific, space-occupying solitary
tumoral presentation of AL is called amyloidoma; regarding
LCDD, the corresponding term aggregoma was suggested
by Rostagno et al. in 2002. He first reported 3 patients
who had tumoral masses of non-amyloid κ-light chain
aggregates: 2 with cervical masses and 1 with a solitary lung
nodule [11]. To date, 50 cases of cerebral-restricted AL
have been reported [14-16]. In addition to 30 intracerebral
solitary amyloidomas that mainly exhibited λ-type amyloids
(but in some cases both λ- and κ-type amyloids), 20 further
cases that exclusively demonstrated λ-type amyloids were
published [14,16]. The latter included 8 cases of restricted
AL with intracranial plasmocytomas; 2 cases with PCNSL;
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with multiple sclerosis; and 3 cases with widespread
subcortical vascular amyloidosis with leukoencephalopathy
(WSVAL). For further details, see the review by Schröder
and colleagues [15]. By contrast, excluding our case, only 3
intracerebral LCDD cases were previously reported: 2
diffuse manifestations of λ-light chain aggregates
[17,18] and 1 case of vascular presentation of non-
amyloid λ-light chain aggregates, designated as cerebral
LCDD vasculopathy (CLCDDV) [19]. For details about
these cases see “Additional file 1”.
The case presented here is the first report on tumoral
presentation of a brain-restricted LCDD that can be
called an aggregoma. To create a better understanding of
the relationships of the involved diseases they were
classified in a pedigree (Figure 5); an overview of the
details of the different manifestations of MIDD, AL
and LCDD is provided in Table 1.
In systemic amyloidosis or LCDD, the CNS is usually
not affected because of the blood–brain-barrier (BBB),
which protects the brain sufficiently from circulating harm-
ful metabolites (e.g., misfolded proteins) [20]. Nevertheless,
54 cases of either brain-restricted amyloid or non-amyloid
deposition diseases, including our case, have been reported
thus far (Table 1). Most of the depositions were located in
the subcortical periventricular white matter, a preferred
location for B-cell lymphoma [5]. Plasma cells were
associated with deposits in many of the published cases
with proof of monoclonality in some cases, suggesting
isolated intracerebral production of monoclonal immuno-
globulins by monoclonal B-cell lymphocytes [15,19,21]. It
appears that the BBB exerts its function of controlling theFigure 5 Schematic of classification of the disease. Pathological present
diseases (MIDD), light chain-derived amyloidosis (AL) and light chain depositio
of the reported case within the pedigree is highlighted in bold letters and lin
vasculopathy; PCNSL = Primary central nervous system lymphoma; ICA = Intra
amyloidosis with leukoencephalopathy.exchange of metabolites in both directions because in
none of the 54 cases were other organ systems involved.
In both isolated cerebral LCDD and AL, it has been
shown that brain deposits mainly consist of λ-type
light chains that form either amyloid or non-amyloid
aggregations. Only in 5 cases of ICA were both κ- and λ-
type amyloids demonstrated [16-19]. It is not clear why
the same proteins demonstrate different behaviors of
aggregation; however, there is evidence that both the
micro-environmental conditions and intrinsic amino
acid sequence determine protein aggregation behavior
[18]. To date, all 3 published aggregoma studies revealed
κ-light chains, exclusively [11]. Hence, under micro-
environmental conditions that are not associated with the
formation of amyloids, tumoral aggregation of light chains
could be restricted to the sequence of κ-light chain
amino acids. However, we provide evidence of a tumoral
formation of λ-light chain deposits, which confounds
this notion.
As in other neurological diseases, the clinical presenta-
tion of MIDD depends mainly on the location of
protein deposition and not on the histological finding.
The major clinical signs of LCDD in the brain are epileptic
seizures, cognitive impairments, headaches, and in the
case presented here, hemiparesis, all of which were the
main neurological symptoms observed in intracerebral
amyloidoma (Table 1; for details, see Additional file 1).
Cerebral imaging techniques such as CT and MRI are
rarely specific for the diagnosis of the underlying
histopathology. In the case presented here, we observed a
tumor mass that was hypointense in T1-weighted scans
and isointense to hyperintense in T2-weighted scans withation of both entities of monoclonal immunoglobulin deposition
n disease (LCDD) in relation to the underlying disorders. The assignment
es. CAA = Cerebral amyloid angiopathy; CLCDDV = Cerebral LCDD
cerebral amyloidoma, WSVAL = Widespread subcortical vascular
Table 1 Summary of findings of intracerebral light chain deposition diseases (No. 1–4) in comparison to intracerebral
amyloidomas (No.5)
No. and Source 1 2 3 4 5*
Fischer et al. [18]
2006
Popovic et al. [19]
2007
Pantazis et al. [17]
2010
Present case Foreid et al. [16] 2010
Fischer et al. [14] 2007
- (1935–2010) -
Age 19 35 72 61 49 (15–71)





A) Progressive Focal epileptic
seizure (hemiparesis)
Hemiparesis Epileptic seizures (12)
bulbar palsy Hemiparesis (6)
B) Putative Gait disturbance (2)
Paranoid Visual impairment (4)




No A) 1 ½ years 8 years 3 ½ years NA
B) 13 years







gyrus rectus & periventricular
parietal lobe
Cortical (1)
periventricular Subcortical & cortical (8)








NA in detail T1 + GL: T1: Hypointense CT: Hyperdense
Not enhanced T1+GL: Enhanced CT+CM: Enhanced
T2: Hyperintense T1: Hypointense
T2: Iso- to T1+GL: Enhanced
hyperintense T2: Iso- to
hyperintense





















- around blood vessels
- Infiltrating T-cells - within vessel wall - Infiltrating T-cells Infiltrating T-cells - within vessel wall
- Monoclonal
B- cell proliferation

















- Plasma cells: λ-light
chain >> κ-light chain
- Ki67: 2% - Ki67: 3% - 7–12-nm fibrils
- Ki67: 1-3% - CD3+, CD5+, CD20+,
CD23-, Cyclin D-
- CD5+, CD38+, CD19+,
CD10, CD79a-, CD138-
- CD20+, CD5+, CD3+
CD38+, CD19-, CD10-,
MUM1-, bcl6-
- λ-light chain ++ 14/16
- κ-light chain + 2/16
* N = X/30, number of patients with the presented characteristics of all presented cases of all N=30 intracerebral amyloidomas.
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These MRI characteristics are also usually observed in
ICA (Table 1; for details, see Additional file 1). Other
published cases of brain-isolated LCDD showed similar
MRI properties but a more diffuse protein deposition
similar to other brain diseases such as low-grade astrocyto-
mas, cerebral lymphomas and inflammatory diseases of the
white matter.
Because both, the clinical presentation and imaging
features of various cerebral disorders are not specific,
histological analysis functions as a pivot point for further
therapeutic strategy. Depending on the location of the
disease, the distinction of adjacent healthy brain tissue
and the involvement of eloquent areas, a straightforward
surgical removal, or an open alternative stereotactical
biopsy would be the methods of choice. For ICA, it is
known that medical treatment is not successful, but
surgical removal has a good prognosis if the tumor can
be removed completely [22,23]. For cerebral-restricted
LCDD, only data from the therapy of 2 cases are available
thus far and only for a time period of 24 months at the
longest. Fischer et al. reported that after 3 cycles of
methotrexate, the disease was steady for at least 24
months after the onset of symptoms and even a slight
decrease in lesion size was observed by MRI after 6
months (for details, see Additional file 1, Case I).
Although Pantazis and colleagues also demonstrated
stability of the disease by 20 months after chemotherapy
with Rituximab (MabThera™, Rituxan™), Trofosfamide
(Ixoten™) and steroids, the control MRI new lesions after
16 months (for details, see Additional file 1, Case III). The
data suggest that chemotherapy can provide at least a
temporary benefit for disease progression but is most
likely not sufficient to cure the disease possibly because of
the drugs that cannot enter the brain across the intact
BBB in sufficient levels to exert their full effect. One
would assume an even weaker effect on aggregomas
because penetration of the drugs across the BBB into the
space-occupying lesion is strongly impaired, as it was also
demonstrated for ICA [22].
Conclusion
MIDD is a very rare and obscure manifestation of primary
central nervous system low-grade lymphoma. The disease
is characterized by monoclonal production of immuno-
globulins that can occur in an isolated manner in the
brain due to the BBB. The case on tumoral aggregation of
λ-light chain deposits presented here, confounds the
former assumption that tumoral aggregation of light
chains is restricted to κ-light chain amino acids. To date,
only 53 cases of MIDD have been published, including 50
cases of cerebral-restricted light chain-derived amyloidosis
and 3 cases of the even less frequent non-amyloid light
chain deposition disease. In the case presented here, thelesion was located in an eloquent area of the brain, which
necessitated 2 stereotactic biopsies, both of which were
performed at other hospitals (one in June 2007 and the
other in July 2008) and demonstrated no evidence of
malignancy or inflammation. However, the patient showed
continuous tumor progression and clinical deterioration.
After resection, histopathological examination determined
that most of the tumor consisted of large, amorphous,
proteinaceous, eosinophilic deposits with small islands
of lymphoid cells between the deposits. The lack of
awareness of LCDD and its unique histological presenta-
tion contribute to the risk of misdiagnosis and underscore
the need for a careful description of this disease and the
limitations of biopsy. To date, the best therapeutic strategy
for this disease remains controversial because the impact
of surgical removal, radiotherapy and chemotherapy
cannot be reliably evaluated due to the low number
of cases thus far.
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